Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06159335
Other study ID # 2023-1082
Secondary ID Protocol Version
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 10, 2024
Est. completion date December 2024

Study information

Verified date March 2024
Source University of Wisconsin, Madison
Contact Suzanne Hanson
Phone 608-263-9179
Email radstudy@uwhealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.


Description:

The purpose of this research is to utilize new imaging methods to aid in assessing whether imaging shows presence of tumor. Developing imaging technologies is critical for more accurately identifying location and amount of tumor, which will then lead to improvements in future cancer therapy. This study aims to evaluate imaging methods known as PET and MRI to improve detection of cancerous tissue better than the types of imaging that are currently available. These methods are conducted on the same machine as conventional MRI that uses a powerful magnet, radio waves, and a computer to create detailed images. Both the PET and MRI methods look at the number of proteins a tumor has. The more proteins, the more likely there is tumor relative to normal brain tissue.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older - Able and willing to provide informed consent - Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI - Received at least one immune checkpoint inhibitor for treatment of the malignancy in the past 6 months - Any other concurrent therapy or prior administered therapy, which would include prior surgery, radiation, immunotherapy, or chemotherapy are not an exclusion. - Has had at least one previous standard-of-care MRI imaging within the past 60 days for assessment of disease location and extent with increasing enhancement where the question of tumor recurrence versus treatment related change are a clinical question. - Be able to lie still for 30-60 minutes during the imaging procedure - Willing and able to undergo PET/MRI Exclusion Criteria: - Subject unable or unwilling to provide informed consent - Subject is pregnant - Subject with contraindication(s) to or inability to undergo a PET or MRI - Known allergy to 18F-Fluciclovine or any of its excipients

Study Design


Intervention

Radiation:
F-Fluciclovine radiotracer
Participants will receive PET radiotracer and MRI

Locations

Country Name City State
United States University of Wisconsin Madison Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison Blue Earth Diagnostics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Amino acid uptake into tumor tissue Using 18F-Fluciclovine PET, compare amino acid uptake into brain tumor tissue with uptake in normal brain tissue. Higher uptake is hypothesized to indicate malignancy 3 hours
Primary Cystolic protein in tumor cells Using MR CEST, measure the level of cystolic protein in tumor cells relative to normal brain tissue. Higher levels are hypothesized to indicate malignancy. 3 hours
See also
  Status Clinical Trial Phase
Completed NCT04324645 - Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Completed NCT01635270 - Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma Phase 2
Terminated NCT03724422 - HO Prophylaxis Therapy for Distal Humerus Fractures N/A
Recruiting NCT03731130 - Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT05721053 - Improving Outcomes for Older Adults Undergoing Radiation Therapy
Active, not recruiting NCT04764227 - Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Phase 2
Not yet recruiting NCT05821452 - Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma Phase 2
Recruiting NCT05335148 - Study to Evaluate the Safety of Colchicine Phase 1
Recruiting NCT04362306 - Radiation Oncology Patient Medical Physics Intervention Study N/A
Completed NCT01917890 - Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer N/A
Not yet recruiting NCT05648253 - Hyivy Device in Post-radiation Patients N/A
Completed NCT03235427 - The CAROLE (CArdiac Related Oncologic Late Effects) Study
Recruiting NCT03142425 - Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy
Recruiting NCT05406063 - Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases N/A
Recruiting NCT03213925 - Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer Phase 2
Recruiting NCT03071289 - A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer Phase 3
Recruiting NCT06128863 - Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Phase 2
Recruiting NCT05351294 - Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet Phase 3